The MIF −173G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population

Xue, Yue; Xu, Hongyan; Rong, Liucheng; Lü, Qing; Li, Jie; Tong, Na; Wang, Meilin; Zhang, Zhengdong; Fang, Yongjun

doi:10.1016/j.leukres.2010.03.030

Cited by 25 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first site consists of the CATT repeat at -794 which repeats 5-8 times (Baugh et al, 2002) and the site is within a potential pituitary 1 (PIT-1) transcription factor binding site (Bifulco et al, 2008). The second site is a single nucleotide polymorphism at -173(G/C) (Xue et al, 2010). This site is associated with enhanced promoter activity in some cancer cell lines and the activity is proportional increased MIF levels in serum (Xue et al, 2010).…”

Section: Genetics and Structure Of Mifmentioning

confidence: 99%

See 1 more Smart Citation

Macrophage Migration Inhibitory Factor: a Potential Marker for Cancer Diagnosis and Therapy

Babu¹,

Chetal²,

Kumar³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Macrophage migration inhibitory factor (MIF) is a pluripotent cytokine which plays roles in inflammation, immune responses and cancer development. It assists macrophages in carrying out functions like phagocytosis, adherence and motility. Of late, MIF is implicated in almost all stages of neoplasia and expression is a feature of most types of cancer. The presence of MIF in almost all tumors and all stages of cancer makes it an interesting candidate for cancer therapy. This review explores the roles of MIF in neoplasia.

show abstract

Section: Genetics and Structure Of Mifmentioning

confidence: 99%

“…The second site is a single nucleotide polymorphism at -173(G/C) (Xue et al, 2010). This site is associated with enhanced promoter activity in some cancer cell lines and the activity is proportional increased MIF levels in serum (Xue et al, 2010).…”

Section: Genetics and Structure Of Mifmentioning

confidence: 99%

Macrophage Migration Inhibitory Factor: a Potential Marker for Cancer Diagnosis and Therapy

Babu¹,

Chetal²,

Kumar³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…These studies thus suggest that an association exists between Mif promoter genotypes that result in increased MIF protein production and an increased risk of inflammatory disease. Similarly, studies examining the association between Mif promoter polymorphisms and cancer have reported an increased risk of cancer for patients with higher MIF protein producing promoter genotypes [3,27-30] while others have reported a lack of association [31]. The aim of this study is to conduct a meta-analysis of all available studies that examine the association between Mif promoter polymorphism and the incidence of cancer.…”

Section: Introductionmentioning

confidence: 99%

Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a meta-analysis

Vera

Meyer-Siegler

2011

BMC Res Notes

View full text Add to dashboard Cite

BackgroundMacrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine upstream of many inflammatory cytokines. MIF is implicated in several acute and chronic inflammatory conditions. MIF's promoter region has functional single nucleotide polymorphisms that controls MIF expression and protein levels. Since increased plasma MIF levels are associated with cancer, studies have examined the association between Mif promoter polymorphisms and cancer. This study is a meta-analysis of the available studies on such an association.ResultsA total of 5 studies were included in this meta-analysis to include 1116 cases (cancer patients) and 1728 controls (no cancer). Carrying any C allele in the Mif -173 G/C promoter polymorphism resulted in a significantly greater risk for developing cancer [OR = 1.89 (1.15-3.11), p = 0.012)] when compared to the (G/G) genotype. Subgroup analysis revealed that this association was significant only for "solid" tumors (including gastric and prostate cancers) [OR = 2.67 (1.26-5.65), p = 0.010] but not for "non-solid" tumors (leukemia) [OR = 1.21 (0.95-1.55), p = 0.122]. Furthermore, when only prostate tumor studies were included in the analysis, the association became even stronger [OR = 3.72 (2.55-5.41), p < 0.0001].ConclusionsMeta-analysis suggests there is an association between any C allele in the Mif -173 G/C promoter polymorphism and an increased risk of cancer, particularly for solid tumors. The association appeared stronger for prostate cancer, specifically. Future studies that include different types of cancers are needed to support and extend these observations.

show abstract

“…Meyer-Siegler et al (16) found that the incidence of prostate cancer was significantly increased among GC and CC genotype carriers. Xue et al (20) found that the MIF-173G/C polymorphism was an etiological factor in childhood acute lymphoblastic leukemia and identified it as a potential candidate gene for assessing susceptibility to this malignancy. This study adopted a restriction fragment length polymorphism polymerase chain reaction to analyze the genotype of patients and healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Correlation of macrophage migration inhibitory factor gene polymorphism with the risk of early-stage cervical cancer and lymphatic metastasis

Lian

Tao

et al. 2011

Oncology Letters

View full text Add to dashboard Cite

Abstract. Associations of functional single nucleotide polymorphisms in MIF-173G/C with early stage cervical cancer were investigated in a hospital-based case-control study on 250 patients with cervical cancer prior to surgery (including 49 cases with and 201 cases without lymphatic metastasis) and 147 healthy controls. The polymorphism was assessed using restriction fragment length polymorphism polymerase chain reaction, and the MIF serum concentration was examined using the enzyme-linked immunosorbent assay to analyze the correlation between the polymorphism and the MIF serum concentration. Carriers of the variant C allele in MIF-173 were at a significantly higher risk of cervical cancer compared to carriers of the wild-type allele (aOR=1.508; 95% CI, 1.128-2.016, p=0.05). The GC and CC genotypes may be the causative factors for cervical cancer (aOR=1.851; 95% CI, 1.132-3.027, p=0.013). Individuals with the GC+CC genotype and C allele at the MIF-173G/C site were at a significantly higher risk of cervical cancer and lymphatic metastasis. The risk of lymphatic metastasis in early stage cervical cancer was increased more than 1.6 times in patients with the CC and GC genotypes compared with those with the GG genotype. The genotype distribution and allele frequency of MIF-173G/C were statistically significant in the well-, moderately and poorly differentiated groups (P<0.05). Compared to the GG genotype and G allele, patients with GC and CC genotypes and C allele exhibited a lower degree of differentiation and a higher degree of malignancy. A significant difference was observed in MIF serum concentrations among the various subgroups (P<0.05). The early cervical cancer, lymphatic metastasis and poorly differentiated groups exhibited higher MIF levels in serum. Moreover, patients with the CC genotype exhibited higher MIF serum concentration, which could increase the risk of early stage cervical cancer and lymphatic metastasis. The results presented in this study provide the first evidence that the genetic polymorphism MIF-173 is associated with cervical cancer in humans. Detection of MIF serum concentration and genotyping may be used as biomarkers for early diagnosis and therapy for cervical cancer.

show abstract

The MIF −173G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population

Cited by 25 publications

References 33 publications

Macrophage Migration Inhibitory Factor: a Potential Marker for Cancer Diagnosis and Therapy

Macrophage Migration Inhibitory Factor: a Potential Marker for Cancer Diagnosis and Therapy

Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a meta-analysis

Correlation of macrophage migration inhibitory factor gene polymorphism with the risk of early-stage cervical cancer and lymphatic metastasis

Contact Info

Product

Resources

About